Experienced in Hemoglobin C Disease

Dr. Stephen W. Gilheeney

Pediatric Hematology Oncology
Memorial Sloan Kettering Cancer Center, 1275 York Avenue, 
New York, NY 
Clinical Trials:Currently Recruiting for 2 Trials
Experienced in Hemoglobin C Disease
Memorial Sloan Kettering Cancer Center, 1275 York Avenue, 
New York, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Stephen Gilheeney is a Pediatric Hematologist Oncology provider in New York, New York. Dr. Gilheeney is rated as an Experienced provider by MediFind in the treatment of Hemoglobin C Disease. His top areas of expertise are Medulloblastoma, Embryonal Tumor with Multilayered Rosettes, Glioma, and Sickle Cell Disease.

His clinical research consists of co-authoring 33 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Pediatric Hematology Oncology
Licenses
Pediatric Hematology-Oncology in NY
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Health First
  • HMO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
MetroPlus Health
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 1 Less Insurance Carrier -

Locations

Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021

Additional Areas of Focus

Dr. Gilheeney has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated With BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated With BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
Enrollment Status: Recruiting
Publish Date: October 15, 2025
Intervention Type: Procedure, Drug, Other
Study Drugs: Carboplatin, Selumetinib Sulfate, Vincristine Sulfate
Study Phase: Phase 3
A Phase 2 Trial of Chemotherapy Followed by Response-Based Whole Ventricular &Amp; Spinal Canal Irradiation (WVSCI) for Patients With Localized Non-Germinomatous Central Nervous System Germ Cell Tumor
A Phase 2 Trial of Chemotherapy Followed by Response-Based Whole Ventricular &Amp; Spinal Canal Irradiation (WVSCI) for Patients With Localized Non-Germinomatous Central Nervous System Germ Cell Tumor
Enrollment Status: Recruiting
Publish Date: September 22, 2025
Intervention Type: Drug, Procedure, Biological, Radiation, Other
Study Drugs: Carboplatin, Etoposide, Filgrastim, Ifosfamide, Mesna, Pegfilgrastim, Thiotepa
Study Phase: Phase 2
An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib)
An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib)
Enrollment Status: Active_not_recruiting
Publish Date: September 24, 2025
Intervention Type: Drug
Study Drugs: Dabrafenib, Trametinib
Study Phase: Phase 4
A Phase 2 Study of Dabrafenib (NSC# 763760) With Trametinib (NSC# 763093) After Local Irradiation in Newly-Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG)
A Phase 2 Study of Dabrafenib (NSC# 763760) With Trametinib (NSC# 763093) After Local Irradiation in Newly-Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG)
Enrollment Status: Active_not_recruiting
Publish Date: September 18, 2025
Intervention Type: Procedure, Radiation, Drug
Study Drugs: Dabrafenib Mesylate, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 2
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Enrollment Status: Active_not_recruiting
Publish Date: August 12, 2025
Intervention Type: Drug, Procedure, Radiation, Other
Study Drugs: Cisplatin, Cyclophosphamide, Lomustine, Vincristine, Vincristine Sulfate
Study Phase: Phase 2
A Phase 3 Study of Selumetinib (NSC# 748727) or Selumetinib in Combination With Vinblastine for Non-NF1, Non-TSC Patients With Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations
A Phase 3 Study of Selumetinib (NSC# 748727) or Selumetinib in Combination With Vinblastine for Non-NF1, Non-TSC Patients With Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations
Enrollment Status: Active_not_recruiting
Publish Date: August 07, 2025
Intervention Type: Other, Procedure, Drug
Study Drugs: Selumetinib, Vinblastine
Study Phase: Phase 3
A Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
A Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
Enrollment Status: Active_not_recruiting
Publish Date: July 28, 2025
Intervention Type: Other, Procedure, Drug
Study Drugs: Carboplatin, Selumetinib Sulfate, Vincristine Sulfate
Study Phase: Phase 3
A Phase I Study of Savolitinib in Recurrent, Progressive or Refractory Medulloblastoma, High-Grade Glioma, Diffuse Intrinsic Pontine Glioma, and CNS Tumors Harboring MET Aberrations
A Phase I Study of Savolitinib in Recurrent, Progressive or Refractory Medulloblastoma, High-Grade Glioma, Diffuse Intrinsic Pontine Glioma, and CNS Tumors Harboring MET Aberrations
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Procedure, Drug
Study Drug: Savolitinib
Study Phase: Phase 1
Phase II Open-label Global Study to Evaluate the Effect of Dabrafenib in Combination With Trametinib in Children and Adolescent Patients With BRAF V600 Mutation Positive Low Grade Glioma (LGG) or Relapsed or Refractory High Grade Glioma (HGG)
Phase II Open-label Global Study to Evaluate the Effect of Dabrafenib in Combination With Trametinib in Children and Adolescent Patients With BRAF V600 Mutation Positive Low Grade Glioma (LGG) or Relapsed or Refractory High Grade Glioma (HGG)
Enrollment Status: Completed
Publish Date: December 13, 2023
Intervention Type: Drug
Study Drugs: Dabrafenib, Trametinib, Carboplatin with Vincristine
Study Phase: Phase 2
View 7 Less Clinical Trials

33 Total Publications

Challenging the Odds: Long-Term Survival in Pediatric Diffuse Midline Glioma With H3 K27M and BRAF V600 Co-Mutations Treated With Upfront Radiotherapy and Targeted Therapy.
Challenging the Odds: Long-Term Survival in Pediatric Diffuse Midline Glioma With H3 K27M and BRAF V600 Co-Mutations Treated With Upfront Radiotherapy and Targeted Therapy.
Journal: Pediatric blood & cancer
Published: May 05, 2025
Similar Doctors
Advanced in Hemoglobin C Disease
Dr. Mario A. Peichev
Pediatric Hematology Oncology
Advanced in Hemoglobin C Disease
Dr. Mario A. Peichev
Pediatric Hematology Oncology

Amboy Medical Practice, P.C.

800 Castleton Ave, 
Staten Island, NY 
 (12.2 miles away)
718-818-4570
Experience:
43+ years
Languages Spoken:
English
See accepted insurances

Mario Peichev is a Pediatric Hematologist Oncology provider in Staten Island, New York. Dr. Peichev has been practicing medicine for over 43 years and is rated as an Advanced provider by MediFind in the treatment of Hemoglobin C Disease. His top areas of expertise are Sickle Cell Disease, Hemoglobinopathy, Hemoglobin SC Disease, and Hemolytic Anemia.

Advanced in Hemoglobin C Disease
Dr. Anshul K. Vagrecha
Pediatric Hematology Oncology
Advanced in Hemoglobin C Disease
Dr. Anshul K. Vagrecha
Pediatric Hematology Oncology

North Shore-Lij Medical PC

New Hyde Park, NY 
 (14.7 miles away)
718-470-3000
Languages Spoken:
English
See accepted insurances

Anshul Vagrecha is a Pediatric Hematologist Oncology provider in New Hyde Park, New York. Dr. Vagrecha is rated as an Advanced provider by MediFind in the treatment of Hemoglobin C Disease. His top areas of expertise are Hemophagocytic Lymphohistiocytosis, Multisystem Inflammatory Syndrome in Children (MIS-C), Sickle Cell Disease, and Febrile Neutropenia.

Experienced in Hemoglobin C Disease
Dr. Banu Aygun
Pediatric Hematology Oncology
Experienced in Hemoglobin C Disease
Dr. Banu Aygun
Pediatric Hematology Oncology
New Hyde Park, NY 
 (14.7 miles away)
718-470-3460
Languages Spoken:
English
See accepted insurances

Banu Aygun is a Pediatric Hematologist Oncology provider in New Hyde Park, New York. Dr. Aygun is rated as an Elite provider by MediFind in the treatment of Hemoglobin C Disease. Her top areas of expertise are Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, Hemolytic Anemia, and Splenectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gilheeney's expertise for a condition
ConditionClose
    View All 42 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile